Compare MRT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | ANTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.3M | 170.6M |
| IPO Year | 2021 | 2022 |
| Metric | MRT | ANTX |
|---|---|---|
| Price | $2.03 | $4.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $3.58 | $2.00 |
| AVG Volume (30 Days) | 17.3K | ★ 233.5K |
| Earning Date | 08-08-2018 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $72.36 | N/A |
| Revenue Next Year | $95.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.97 | $1.00 |
| 52 Week High | $3.32 | $6.91 |
| Indicator | MRT | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 61.13 |
| Support Level | $1.99 | $1.06 |
| Resistance Level | $2.27 | $5.14 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 31.67 | 65.04 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.